Ozempic and Addiction Risk: A Fresh Potential Benefit of GLP-1 Drugs

New research suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as Ozempic and Mounjaro, may reduce the risk of developing substance apply disorders and even lower the risk of overdose. Originally developed to treat type 2 diabetes and obesity, these medications are now being investigated for a surprising additional benefit: curbing addiction.

How GLP-1 Drugs May Curb Addiction

The findings stem from analyses of data from the Veterans Affairs (VA) healthcare system. Dr. Ziyad Al-Aly, an epidemiologist at WashU Medicine and VA St. Louis Health Care System, noticed intriguing reports from patients taking GLP-1 drugs. Patients reported a decreased desire for substances like alcohol and even cessation of smoking after starting the medication for diabetes or weight loss.

A large study analyzing data from over 600,000 individuals in the VA system over three years revealed that those treated with GLP-1 drugs had a 15-20% lower risk of developing substance use disorders involving opioids, cocaine, nicotine, alcohol, cannabis, and other substances. The benefit extended to individuals with a history of addiction, showing a reduced risk of drug-related death, overdose, hospitalization, and suicidal attempts. Similar benefits were observed in analyses of both women and younger men.

Researchers believe the mechanism behind this effect involves the brain’s mesolimbic system, the center responsible for reward-signaling, motivation, and stress. GLP-1 drugs appear to reduce dopamine activity in this region, which is often hijacked by addiction.

Broader Benefits and Risks of GLP-1 Receptor Agonists

A comprehensive study published in Nature Medicine in January 2025, analyzed data from over 2 million people with diabetes taking GLP-1RAs. This research identified a range of associations beyond addiction, including a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (like Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, and certain respiratory conditions.

Although, the study also highlighted potential risks associated with GLP-1RA use, including an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis.

What This Means for Addiction Treatment

While these findings are promising, experts caution against widespread use of GLP-1 drugs for addiction treatment until further research is conducted. Dr. Klara Klein, an endocrinologist at the University of North Carolina at Chapel Hill, emphasizes that these medications haven’t been tested in individuals without obesity or type 2 diabetes.

Several large, controlled trials are underway to assess the efficacy and safety of GLP-1 drugs specifically for substance use disorder. These trials will help determine the appropriate duration of treatment and identify which populations may benefit the most. Dr. Lorenzo Leggio, an addiction expert at the National Institutes of Health, expresses hope that these medications could potentially offer a single treatment option for individuals struggling with multiple addictions, which is a common scenario.

Looking Ahead

The emerging evidence regarding GLP-1 drugs and addiction risk is a significant development in the field of addiction medicine. Further research is crucial to fully understand the potential benefits and risks, and to determine how these medications can be best utilized to address the widespread problem of substance use disorder. The possibility of a single medication effective against multiple addictions offers a hopeful prospect for the future of addiction treatment.